Clover Health Investments, Corp. to Release Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Clover Health Investments, Corp. (CLOV) announced it will release its fourth quarter and full year 2025 financial results after market close on February 26, 2026, followed by a webcast at 5:00 p.m. ET. The company, which focuses on providing healthcare to Medicare recipients through its software platform Clover Assistant, will discuss its financial performance and business updates. Investors can register for the webcast through the Investor Relations section of Clover Health's website.
Clover Health Investments, Corp. to Release Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Clover Health Investments, Corp. (CLOV) announced it will release its fourth quarter and full year 2025 financial results after market close on February 26, 2026. Management will host a webcast at 5:00 p.m. ET to discuss the results and business updates. The company is focused on providing healthcare access to Medicare recipients, leveraging its Clover Assistant software platform to improve clinical decision-making and health outcomes.
Clover Health CEO Reynoso sells $11860 in shares By Investing.com
Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, sold 4,597 shares for $11,860 on January 20, 2026, and an additional 14,732 shares for $41,396 on January 15, 2026, to cover tax obligations. Despite the company not being profitable in the last year, InvestingPro projects profitability in the current year, and analysts view the stock as slightly undervalued with price targets between $3.00 and $3.70. Clover Health also reported a significant increase in Medicare Advantage membership and aims for its first full-year GAAP Net Income profitability in 2026, though it missed Q3 2025 EPS estimates while exceeding revenue expectations.
Clover Health CEO Reynoso sells $11860 in shares
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, sold 4,597 shares of Class A Common Stock for $11,860 on January 20, 2026, and an additional 14,732 shares for $41,396 on January 15, 2026, to cover tax obligations. Despite not being profitable in the past year, InvestingPro analysis anticipates Clover Health will achieve profitability this year, with a projected GAAP Net Income profitability in 2026. The company also reported a 53% year-over-year increase in Medicare Advantage membership and its stock is considered slightly undervalued by InvestingPro.
Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November
U.S. stocks traded lower on Wednesday, with the Nasdaq falling significantly, despite energy shares gaining and U.S. retail sales increasing by 0.6% in November. Several companies saw substantial stock movements: High Roller Technologies surged 289% following a new partnership, Clover Health Investments rose 10% on membership growth, and Inspire Veterinary Partners gained 78%. Conversely, BriaCell Therapeutics and Plus Therapeutics dropped over 30% after pricing public offerings, while Hub Cyber Security fell 39% following a reverse stock split.
Clover Health Reports 53% Medicare Advantage Membership Growth and Aims for First Full Year GAAP Net Income Profitability in 2026
Clover Health announced a significant 53% year-over-year increase in its Medicare Advantage membership for 2026, reaching approximately 153,000 members. This growth, driven by strategic market approaches and strong retention, positions the company for its first full year of GAAP Net Income profitability in 2026. Clover's PPO plan, which covers over 97% of its members, leads nationally in clinical quality, supported by its Clover Assistant technology to enhance patient outcomes.
Clover Health announces 53% growth in Medicare Advantage membership during AEP, increasing to 153,000 members as of January 1, 2026; expects first-ever full year GAAP net income profitability in 2026
Clover Health announced a significant 53% growth in its Medicare Advantage membership during the Annual Enrollment Period, reaching 153,000 members as of January 1, 2026. The company also anticipates achieving its first-ever full year GAAP net income profitability in 2026. This positive development signals strong company performance and a promising financial outlook for Clover Health.
Clover Health Investments, Corp. (NASDAQ:CLOV) Given Consensus Rating of "Hold" by Analysts
Five analysts have given Clover Health Investments, Corp. (NASDAQ:CLOV) a consensus "Hold" rating, with an average 1-year price target of $3.23. The company recently reported a loss of ($0.05) EPS against an expected $0.02, while revenue beat expectations at $496.65 million. Clover Health remains unprofitable, with negative return on equity and net margin, and shares are trading around $2.60.
Clover Health Investments, Corp. (NASDAQ:CLOV) Given Consensus Recommendation of "Hold" by Analysts
Clover Health Investments, Corp. (NASDAQ:CLOV) has received a consensus "Hold" recommendation from analysts, with an average 12-month price target of $3.23. The company recently missed EPS expectations but exceeded revenue forecasts, while institutional investors have adjusted their positions in the stock. CLOV shares are currently trading around $2.64 with a market capitalization of $1.36 billion.
Rhumbline Advisers Increases Position in Clover Health Investments, Corp. $CLOV
Rhumbline Advisers significantly increased its stake in Clover Health Investments (NASDAQ:CLOV) by 8,149.2% in the second quarter, now holding 584,459 shares valued at $1.63 million. Despite this increased institutional interest, analysts maintain a "Hold" consensus rating with a target price of $3.93, while the company faces challenges with missed EPS estimates and negative profitability metrics. Several other institutional investors also acquired new positions in CLOV during recent quarters, indicating varied sentiment towards the stock.
Soviero Asset Management LP Acquires 650,000 Shares of Clover Health Investments, Corp. $CLOV
Soviero Asset Management LP significantly increased its stake in Clover Health Investments, Corp. (NASDAQ:CLOV) by 260%, acquiring an additional 650,000 shares to total 900,000 shares worth approximately $2.51 million. Despite a recent EPS miss, the company reported revenue of $496.65 million, surpassing expectations. Analysts currently have a "Hold" consensus rating for CLOV, with an average price target of $3.93.
Clover Health Investments, Corp. (NASDAQ:CLOV) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Clover Health Investments, Corp. (NASDAQ:CLOV) has received a "Moderate Buy" consensus recommendation from six analysts, with an average 12-month price target of $3.93. The company recently reported a quarterly EPS of ($0.05), missing estimates, but revenue beat expectations at $496.65 million. Institutional investors have been increasing their stakes, and the stock currently trades around $2.28.
Clover Health's CFO Peter Kuipers to Present at 2025 Citi Global Healthcare Conference
Clover Health's CFO, Peter Kuipers, is scheduled to present at the 2025 Citi Global Healthcare Conference on December 4, 2025. The presentation will discuss the company's focus on improving healthcare access for Medicare beneficiaries through its Clover Assistant software platform. This engagement aims to increase investor visibility and highlight Clover Health's technological advancements and commitment to enhancing patient outcomes.
Clover Health Investments, Corp. (CLOV) Reports Break-Even Earnings for Q3
Clover Health Investments (CLOV) reported break-even quarterly earnings, surpassing the Zacks Consensus Estimate of a $0.02 loss per share for Q3 2025, and also exceeded revenue expectations with $496.65 million. The company has shown favorable estimate revisions recently, earning a Zacks Rank #2 (Buy), suggesting potential market outperformance. This positive outlook is supported by a 16.8% stock gain year-to-date, slightly outpacing the S&P 500.
Clover Health's CFO Peter Kuipers to Present at 2025 Citi Global Healthcare Conference
Clover Health's CFO, Peter Kuipers, is scheduled to present at the 2025 Citi Global Healthcare Conference on December 4, 2025, to discuss the company's commitment to improving healthcare access for Medicare patients through its Clover Assistant software platform. The company aims to enhance clinical decision-making, improve health outcomes, and reduce healthcare costs. The presentation will be webcast live on Clover Health's investor relations website, allowing investors to learn more about the company's technology and market potential.
Clover Health (Nasdaq: CLOV) posts 50% revenue growth to $497M in the third quarter
Clover Health reported Q3 2025 results showing a 50% year-over-year revenue increase to $496.7 million and a 35% rise in Medicare Advantage membership to 109,226. Despite a GAAP net loss of $24.4 million, the company achieved positive Adjusted EBITDA of $2.1 million for the quarter and $45 million year-to-date. Clover Health also raised its full-year 2025 guidance for average MA membership, insurance revenue, and Adjusted EBITDA, citing cohort economics and favorable CMS developments aimed at improving future profitability.
CLOVER HEALTH INVESTMENTS, CORP. /DE SEC 10-K Report
Clover Health Investments, Corp. released its annual Form 10-K report, detailing an 8.8% increase in total revenues to $1,371.1 million and a significant reduction in net loss to $(43.0) million. The company reported substantial Medicare Advantage membership growth and improved CMS Star ratings, while also launching Counterpart Health to expand its technology's reach. The report outlines future outlooks, strategic initiatives, and challenges including profitability, operational risks, and a competitive landscape.
Clover Health Investments, Corp. Announces Step Down of Chelsea Clinton as from Board and Member of Talent and Compensation Committee and the Nominating and Corporate Governance Committee, Effective October 31, 2025
Clover Health Investments, Corp. announced that Chelsea Clinton will step down from its Board of Directors, effective October 31, 2025. Ms. Clinton, the longest-serving board member since early 2017, contributed significantly to the company's growth from a private entity to a publicly traded organization serving over 100,000 seniors. During her tenure, she served on the Talent & Compensation Committee and the Nominating and Corporate Governance Committee.
Clover Health Investments (NASDAQ:CLOV) Stock Price Up 8.7% - Here's What Happened
Clover Health Investments (NASDAQ:CLOV) saw its stock price increase by 8.7% during mid-day trading to $3.18. Analyst ratings resulted in an average "Hold" with a consensus price target of $4.03, despite some lowering price targets. Insider transactions show CEO Conrad Wai selling shares while Director Anna U. Loengard significantly increased her stake.
Clover Health Reaffirms Strong Growth Potential and Profitability Strategy Amid 2026 Star Ratings Announcement
Clover Health remains confident in achieving above-market membership growth and increasing Adjusted EBITDA profitability through 2027, despite its Medicare Advantage plans receiving 3.5 Stars for PPO and 4.0 Stars for HMO for the 2026 rating year. CEO Andrew Toy emphasizes that Clover's technology-driven approach, powered by Clover Assistant, enables it to deliver excellent healthcare outcomes and drive profitability independently of these Star ratings. The company continues to demonstrate strong clinical quality with high HEDIS scores and actively engages with CMS to advocate for a Star ratings methodology that better reflects actual health outcomes.
Clover Health Investments Corp (CLOV) Unveils Availity Essential for Administrative Tasks
Clover Health Investments Corp (CLOV) has launched Availity Essentials, a new portal designed to improve administrative efficiency for healthcare providers. This platform aims to streamline core tasks, reduce delays in patient care, and allow providers to focus more on patients. CEO Jamie Reynoso emphasized its role in easing administrative burdens and fostering better collaboration between health plans and providers.
Clover Health Investments, Corp. Partners with Availity to Enhance Provider Efficiency and Improve Patient Care
Clover Health Investments, Corp. has partnered with Availity to improve provider efficiency and patient access to care for Medicare beneficiaries. This multi-phase initiative aims to streamline administrative tasks like prior authorizations and eligibility checks through a new centralized portal, reducing burdens on healthcare providers. The collaboration underscores Clover Health's commitment to operational excellence, interoperability, and enhancing the patient experience by allowing providers to focus more on delivering quality care.
Loengard Anna U buys Clover Health investments (CLOV) shares By Investing.com
Anna U. Loengard, a director at Clover Health Investments Corp (NASDAQ:CLOV), purchased $68,755 worth of Class A Common Stock on August 13, 2025. This insider buying occurred as the stock saw an 18.5% surge in the past week and InvestingPro analysis suggests it is fairly valued. The purchases were made for custodial IRAs benefiting her children and align with broader management confidence, as indicated by active share buybacks and analyst targets ranging from $2.50 to $5.00.
Clover Health rises after former CEO buys shares
Clover Health's stock rose after its former CEO purchased shares. This often signals to investors that company insiders have confidence in its future prospects, potentially leading to increased market value.
Clover Health CEO Reynoso sells $19,718 in shares
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, sold 6,823 shares of Class A Common Stock for $19,718 on August 4, 2025, under a Rule 10b5-1 trading plan. Despite the stock having declined 47.7% in six months, Clover Health recently reported Q2 2025 revenue of $477.62 million, surpassing analyst expectations. The company's management has also been actively buying back shares.
Clover Health Earnings Reveal Massive Growth: Revenue Jumps 34%, Medicare Membership Soars Past 106,000
Clover Health reported strong Q2 2025 results, with Medicare Advantage membership growing 32% year-over-year to 106,323 and total revenues increasing 34% to $478 million. Despite a GAAP net loss of $11 million, the company achieved Adjusted EBITDA and Adjusted Net income of $17 million each. Clover Health also updated its full-year 2025 guidance, increasing Medicare Advantage membership expectations and improving Adjusted SG&A projections, while attributing its success to its technology-first approach and the effectiveness of its AI-driven Clover Assistant in reducing hospitalizations and readmissions.
Why Is Clover Health (CLOV) Stock Soaring Today
Clover Health (CLOV) stock surged 9.5% today, driven by overall positive market sentiment ahead of a busy corporate earnings week. Despite previous volatility and a recent insider stock sale that caused a dip, the company's shares gained momentum as more than 85% of S&P 500 companies reporting earnings exceeded expectations. The rally occurred in the absence of any specific new catalysts for Clover Health.
Clover Health Investments, Corp. CFO Peter Kuipers to Present at Canaccord Genuity 45th Annual Growth Conference
Clover Health Investments, Corp. announced that CFO Peter Kuipers will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 11:00 a.m. ET. The company, which focuses on providing affordable, high-quality healthcare to seniors through its software platform, Clover Assistant, will make the presentation accessible via a live webcast on its investor relations website. This event is expected to highlight Clover Health's technology and its positive impact on patient outcomes and cost reduction.
Clover Health CEO Wai Conrad sells $49561 in shares
Clover Health CEO Wai Conrad sold 15,203 shares of Class A Common Stock for $49,561 on July 8, 2025, through a pre-arranged trading plan. Despite the sale, Conrad still directly holds 1,613,498 shares, and the company has shown strong financial health, with a 127% return over the past year. Clover Health also reported robust Q1 2025 results, including a 33% revenue increase and 30% Medicare Advantage membership growth, leading to raised full-year guidance.
Clover Health Investments, Corp. to Release Second Quarter 2025 Financial Results and Host Conference Call on August 5
Clover Health Investments, Corp. will release its Q2 2025 financial results after market close on August 5, 2025, followed by a conference call and webcast at 5:00 p.m. ET to discuss the company's performance. The company, which focuses on providing healthcare solutions for seniors using its Clover Assistant software, will make the webcast accessible via its Investor Relations website. This announcement comes amidst recent insider stock sales and varied institutional investor activity.
From Losses to Profits: How Clover Health Turned Around Its Financials and What's Next
Clover Health has achieved a significant financial turnaround in 2024, reporting a $70 million Adjusted EBITDA profit and a substantial improvement in its Insurance Benefits Expense Ratio (BER) to 81.2%. The company projects robust growth for 2025, including a 37% increase in insurance revenue and a 30% rise in Medicare Advantage membership, driven by its technology-first approach with the Clover Assistant platform and an upcoming 4.0 Star Rating. These improvements align with the company's strategy of leveraging AI-driven care management for better clinical outcomes and cost control, positioning them for sustained profitability and growth in the competitive Medicare Advantage market.
Clover Health to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Clover Health Investments, Corp. (CLOV) will announce its fourth quarter and full year 2024 financial results after market close on February 27, 2025. Following the release, management will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the results. The company, which provides Medicare Advantage plans and uses its Clover Assistant technology to improve healthcare outcomes, has seen significant institutional investor activity in Q4 2024.
10 Best-Performing Stocks in 2024
This article identifies the top 10 best-performing stocks of 2024 from U.S. exchanges with market capitalizations over $1 billion, highlighting their significant year-to-date gains. The stocks span various sectors including biotechnology, fintech, and advanced nuclear energy, with companies like GeneDX Holdings Corp. and Sezzle Inc. leading the pack. Each company's performance is attributed to specific financial achievements, clinical trial successes, or strategic business developments throughout the year.
News Briefs: Clover Health Says SEC Will Not Pursue Enforcement Action
Clover Health Investments Corp. announced that the U.S. Securities and Exchange Commission (SEC) will not pursue an enforcement action following a yearslong investigation into the insurer's business practices. The SEC informed Clover Health on September 26 that it had concluded its investigation. This development follows a prior 2021 probe sparked by a Hindenburg Research report and earlier shareholder class action lawsuits related to a Department of Justice investigation.
Insurtech company Clover Health will exit the ACO REACH program
Clover Health announced its exit from the ACO REACH Program at the end of the 2023 performance year, citing a lack of clear path to profitability despite achieving other goals. The company plans to focus resources on its Medicare Advantage insurance business, which has shown greater and swifter strides toward profitability. This decision follows a tumultuous financial year for Clover Health, including a securities class action settlement and other legal agreements.
Clover Health settles lawsuits alleging that it hid a federal probe from investors
Clover Health has reached a settlement in multiple lawsuits alleging the Medicare Advantage insurtech concealed a federal probe from investors during its 2021 initial public offering. The settlement includes an agreement to improve corporate governance and avoids monetary payment from Clover Health, though fees for plaintiffs' counsel are pending. This resolution aims to allow the company to focus on its mission and profitability goals, following recent improvements in its medical cost ratio despite a decrease in first-quarter 2023 revenues.
$22M Clover Health settlement resolves claims insurance provider covered up DOJ probe
Clover Health Investments Corp. has agreed to a $22 million class action settlement to resolve claims it covered up a U.S. Department of Justice probe while preparing to go public. Investors alleged that Clover Health's shares dropped significantly after a short-seller's report revealed the previously undisclosed DOJ investigation into potential False Claims Act violations. The company plans to cover the settlement primarily from insurance proceeds, with an out-of-pocket payment of $2.5 million.
Delaware Court Finds Broad D&O Coverage for Directors and Officers in SPAC Claim
A Delaware court issued a significant ruling in a D&O liability claim involving a SPAC, Clover Health Investments Corp. v. Berkley Insurance Co., holding that post-merger directors and officers were "Insured Persons" under the SPAC's D&O policy due to "functionally equivalent" roles. The court also made pro-policyholder rulings on coverage for government investigations and allocation of defense costs under the Larger Settlement Rule, which have broader implications for D&O claims in Delaware. This decision provides an expansive view of D&O coverage for SPACs and reinforces policyholder-friendly interpretations of ambiguous policy language.
Palihapitiya Faces Clover Health Lawsuit After Misleading Investors
Billionaire Chamath Palihapitiya is set to face a lawsuit concerning Clover Health after a U.S. judge ruled that allegations of misleading investors surrounding its SPAC merger will proceed. The lawsuit claims that Clover Health executives made materially false statements regarding a DOJ investigation, misleading sales practices, and undisclosed third-party deals. This news led to a 5.35 percent drop in CLOV stock on March 2nd, adding further risk to the company which has seen an 88.35 percent decrease since its June 2021 peak.
CLOV Stock: 5 SPACs That Barry Sternlicht Would Buy Over Clover Health
This article discusses billionaire Barry Sternlicht’s recent comments calling Clover Health a "fraud" and evaluates five SPACs he has been involved with, suggesting which ones might be better investment opportunities than CLOV stock. It highlights Cano Health as a promising investment based on its focus on the Medicare market, while cautioning patience on others still in early stages.
‘SPAC King’ Regains Billionaire Status As Trading Frenzy Boosts Clover Health
Chamath Palihapitiya, known as the "SPAC King," regained his billionaire status after a trading frenzy significantly boosted shares of Medicare Advantage insurer Clover Health. The surge was fueled by Reddit traders targeting the heavily shorted stock, leading to a potential short squeeze. Despite bullish retail investor activity and CEO Vivek Garipalli embracing the Reddit community, analysts like Kevin Fischbeck of Bank of America remain bearish on Clover Health's future membership growth and stock price.
Chamath Palihapitiya's Clover Health Discloses New SEC Investigation And Responds To Short-Seller's Scathing Allegations
Clover Health, backed by Chamath Palihapitiya, disclosed a new SEC investigation into its SPAC acquisition a day after short-seller Hindenburg Research accused the company of misleading investors and failing to disclose an ongoing Department of Justice probe. Clover has stated its intention to cooperate with the SEC and that both the company and Palihapitiya were aware of the DOJ investigation, believing no rules were violated. Shares of Clover Health experienced declines following the allegations.
Clover Health Releases Nov 20 Analyst Day Recording, Announces That The Company Has Applied to List the Combined Company's Common Stock on the Nasdaq Global Select Market Under the Proposed Trading Symbol "CLOV"
Clover Health announced the release of the full recording of its analyst day presentation from November 20, 2020. The company also disclosed that Social Capital Hedosophia Holdings Corp. III has applied to list the combined company's Class A common stock on the Nasdaq Global Select Market under the proposed ticker symbol "CLOV" following their business combination.
